Alembic Pharma
Drug Manufacturers - Specialty & Generic · APLLTD
Mid CapHealthcareMature Stable
Chirayu Amin
Chairman & CEO · Visionary
Company DNA
Hierarchical
About
Alembic Pharma is a Mid Cap company in the Healthcare sector, listed on NSE as APLLTD. With a market cap of ₹14K Cr and revenue of ₹7K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Long-standing legacy pharmaceutical company characterized by family stewardship and established, conservative corporate procedures. Its strategic mandate: To break out of competitive commoditization, the company needs to shift its focus toward high-margin specialty and complex generic R&D.
FAQ
What kind of company is Alembic Pharma?
Alembic Pharma is a Mid Cap Healthcare company (APLLTD) in the Mature Stable phase with a market cap of ₹14K Cr. It is classified as Hierarchical in culture.
What is Alembic Pharma's culture and work environment like?
Alembic Pharma has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Long-standing legacy pharmaceutical company characterized by family stewardship and established, conservative corporate procedures.
Who leads Alembic Pharma?
Alembic Pharma is led by Chirayu Amin (Chairman & CEO), a Visionary leader with 58 years of experience.
What are Alembic Pharma's financials?
Alembic Pharma reported revenue of ₹7K Cr in FY25 with a 5-year revenue CAGR of 7.7%. Operating margin: 11.2%. Market cap: ₹14K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTrusted
LifecycleMature Stable
Long-standing legacy pharmaceutical company characterized by family stewardship and established, conservative corporate procedures.
Mandate
To break out of competitive commoditization, the company needs to shift its focus toward high-margin specialty and complex generic R&D.
To break out of competitive commoditization, the company needs to shift its focus toward high-margin specialty and complex generic R&D.
Financials
Revenue FY25₹7K Cr
PAT FY25₹583 Cr
Rev CAGR 5Y7.7%
OPM11.2%
NPM8.9%
ROE11.2%
ROCE13.7%
P/E21.1
Fwd P/E15.7
P/B2.5
D/E28
Mkt Cap₹14K Cr
Promoter70.6%
Institutional17%
Similar Culture
Could You Lead Alembic Pharma?
Take the Genome Benchmark →